The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Open accessAbstract
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Exposures: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. Main Outcomes and Measures: Overall survival time. Results: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. Conclusions and Relevance: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Patients were grouped based on the estimated number of CD8 TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high ( 20).”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Flexible smoothing with B-splines and penalties
Eilers, P. H. C., & Marx, B. D. (1996) · Statistical Science · doi:10.1214/ss/1038425655 · Cited by 3,666
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“Patients were grouped based on the estimated number of CD8 TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high ( 20).”
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,547
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Self-citationREporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Budczies, J., Klauschen, F., Sinn, B. V., Győrffy, B., Schmitt, W. D., Darb-Esfahani, S., & Denkert, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051862 · Cited by 1,224
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Self-citationCancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S., & Coukos, G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.039 · Cited by 661
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 620
Kroeger, D. R., Milne, K., & Nelson, B. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2762 · Cited by 610
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Self-citationWashington, M. K., Berlin, J., Branton, P., Burgart, L. J., Carter, D. K., Fitzgibbons, P. L., Halling, K., Frankel, W., Jessup, J., Kakar, S., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1539 · Cited by 529
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Phelan, C. M., Kuchenbaecker, K. B., Tyrer, J. P., Kar, S. P., Lawrenson, K., Winham, S. J., Dennis, J., Pirie, A., Riggan, M. J., Chornokur, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3826 · Cited by 502
Self-citationSieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70253-5 · Cited by 433
Self-citationPrognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Self-citationOrigin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Denkert, C., Wienert, S., Poterie, A., Loibl, S., Budczies, J., Badve, S., Bago-Horvath, Z., Bane, A., Bedri, S., Brock, J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.109 · Cited by 285
Self-citationClarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Self-citationGrabowski, J. P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., Ray-Coquard, I., Heitz, J., Traut, A., Pfisterer, J., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.01.022 · Cited by 233
An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
Köbel, M., Rahimi, K., Rambau, P. F., Naugler, C., Le Page, C., Meunier, L., de Ladurantaye, M., Lee, S., Leung, S., Goode, E. L., et al. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000274 · Cited by 221
Self-citationMcMeekin, D. S., Tritchler, D. L., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8722 · Cited by 210
Preston, C. C., Maurer, M. J., Oberg, A. L., Visscher, D. W., Kalli, K. R., Hartmann, L. C., Goode, E. L., & Knutson, K. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080063 · Cited by 208
Self-citationPrognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Tomšová, M., Melichar, B., Sedláková, I., & Šteiner, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.016 · Cited by 186
Endometriosis-Associated Ovarian Cancer: A Review of Pathogenesis
Worley, M., Welch, W., Berkowitz, R., & Ng, S.-W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035367 · Cited by 175
Mesnage, S. J. L., Auguste, A., Genestie, C., Dunant, A., Pain, E., Drusch, F., Gouy, S., Morice, P., Bentivegna, E., Lhomme, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw625 · Cited by 173
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives
Mabuchi, S., Sugiyama, T., & Kimura, T. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e31 · Cited by 166
Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., Larson, M. C., Alsop, K., Dicks, E., Harrington, P., Ramus, S. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2497 · Cited by 161
Self-citationHan, L. Y., Fletcher, M. S., Urbauer, D. L., Müeller, P. R., Landen, C. N., Kamat, A. A., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Deavers, M. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4433 · Cited by 153
Callahan, M. J., Nagymányoki, Z., Bonome, T., Johnson, M. E., Litkouhi, B., Sullivan, E. H., Hirsch, M. S., Matulonis, U. A., Liu, J. F., Birrer, M. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0479 · Cited by 143
Köbel, M., Bak, J., Bertelsen, B. I., Carpén, O., Grove, A., Hansen, E. S., Jakobsen, A. L., Lidang, M., Måsbäck, A., Tolf, A., et al. (2013) · Histopathology · doi:10.1111/his.12349 · Cited by 141
Self-citationEmmanuel, C., Chiew, Y.-E., George, J., Etemadmoghadam, D., Anglesio, M. S., Sharma, R. N., Russell, P., Kennedy, C. J., Fereday, S., Hung, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1292 · Cited by 118
Self-citationAOCS Study Group, Köbel, M., Madore, J., Ramus, S. J., Clarke, B. A., Pharoah, P. D. P., Deen, S., Bowtell, D. D. L., Odunsi, K. O., Menon, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.567 · Cited by 118
Self-citationSurvival in Women With Grade 1 Serous Ovarian Carcinoma
Fader, A. N., Java, J., Ueda, S. M., Bristow, R. E., Armstrong, D. K., Bookman, M. A., & Gershenson, D. M. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31829ce7ec · Cited by 109
Sun, C., Li, N., Ding, D., Weng, D., Li, M., Chen, G., & Ma, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095285 · Cited by 108
Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam, P. (2016) · PubMed · Cited by 106
Köbel, M., Kalloger, S. E., Lee, S., Duggan, M. A., Kelemen, L. E., Prentice, L., Kalli, K. R., Fridley, B. L., Visscher, D. W., Keeney, G. L., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0391 · Cited by 90
Self-citationKar, S., Berchuck, A., Gayther, S. A., Goode, E. L., Moysich, K. B., Pearce, C. L., Ramus, S. J., Schildkraut, J. M., Sellers, T. A., & Pharoah, P. D. P. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0315 · Cited by 49
Self-citationLow-grade epithelial ovarian cancer: a number of distinct clinical entities?
Oswald, A. J., & Gourley, C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000216 · Cited by 34
Ovarian cancer epidemiology in the era of collaborative team science
Cannioto, R. A., Trabert, B. L., Poole, E. M., & Schildkraut, J. M. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0862-6 · Cited by 21
Evaluation of tumor infiltrating lymphocytes in breast cancer
Suganya, U. (2018) · Cited by 12
Cited by
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Pujade-Lauraine, E., Fujiwara, K., Ledermann, J. A., Oza, A. M., Kristeleit, R., Ray-Coquard, I.-L., Richardson, G. E., Sessa, C., Yonemori, K., Banerjee, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00216-3 · Cited by 416
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
Self-citationMonk, B. J., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M. C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00342-9 · Cited by 301
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Metadata
- Authors
- Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Toloczko, A., Hein, A., Bouligny, A. L., Jensen, A., Osorio, A., Hartkopf, A. D., Ryan, A., Chudecka-Glaz, A., Magliocco, A. M., Hartmann, A., Jung, A. Y., Gao, B., Hernandez, B. Y., Fridley, B. L., McCauley, B. M., Kennedy, C. J., Wang, C., Karpinskyj, C., de Sousa, C. B., Tiezzi, D. G., Wachter, D. L., Herpel, E., Taran, F. A., Modugno, F., Nelson, G., Lubinski, J., Menkiszak, J., Alsop, J., Lester, J., García-Donas, J., Nation, J., Hung, J., Palacios, J., Rothstein, J. H., Kelley, J. L., de Andrade, J. M., Robles-Díaz, L., Intermaggio, M. P., Widschwendter, M., Beckmann, M. W., Ruebner, M., Jimenez-Linan, M., Singh, N., Oszurek, O., Harnett, P. R., Rambau, P. F., Sinn, P., Wagner, P., Ghatage, P., Sharma, R., Edwards, R. P., Ness, R. B., Orsulic, S., Brucker, S. Y., Johnatty, S. E., Longacre, T. A., Eilber, U., McGuire, V., Sieh, W., Natanzon, Y., Li, Z., Whittemore, A. S., deFazio, A., Staebler, A., Karlan, B. Y., Gilks, B., Bowtell, D. D., Høgdall, E., Candido dos Reis, F. J., Steed, H., Campbell, I. G., Gronwald, J., Benítez, J., Koziak, J. M., Chang-Claude, J., Moysich, K. B., Kelemen, L. E., Cook, L. S., Goodman, M. T., García, M. J., Fasching, P. A., Kommoss, S., Deen, S., Kjaer, S. K., Menon, U., Brenton, J. D., Pharoah, P. D. P., Chenevix-Trench, G., Huntsman, D. G., Winham, S. J., Köbel, M., & Ramus, S. J.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-12-14
- Volume
- 3
- Issue
- 12
- Pages
- e173290
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2765953690
- Cited by
- 394
- References
- 52
- FWCI
- 34.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.